SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Falk Håkansson Hanna)
 

Sökning: WFRF:(Falk Håkansson Hanna) > (2010-2014) > Fibroblast growth f...

Fibroblast growth factor 10 haploinsufficiency causes chronic obstructive pulmonary disease

Klar, Joakim (författare)
Uppsala universitet,Science for Life Laboratory, SciLifeLab,Medicinsk genetik,Department of Immunology, Genetics and Pathology, Science for Life Laboratory and Rudbeck Laboratory, Uppsala, Sweden
Blomstrand, Peter (författare)
Department of Clinical Physiology, Ryhov County Hospital, Jönköping, Sweden
Brunmark, Charlott (författare)
AstraZeneca RandD, Lund, Sweden
visa fler...
Badhai, Jitendra (författare)
Uppsala universitet,Institutionen för immunologi, genetik och patologi,Science for Life Laboratory, SciLifeLab,Department of Immunology, Genetics and Pathology, Science for Life Laboratory and Rudbeck Laboratory, Uppsala, Sweden
Håkansson, Hanna Falk (författare)
AstraZeneca RandD, Lund, Sweden
Brange, Charlotte Sollie (författare)
AstraZeneca RandD, Lund, Sweden
Bergendal, Birgitta (författare)
National Oral Disability Centre, The Institute for Postgraduate Dental Education, Jönköping, Sweden
Dahl, Niklas (författare)
Uppsala universitet,Medicinsk genetik,Science for Life Laboratory, SciLifeLab,Dahl,Department of Immunology, Genetics and Pathology, Science for Life Laboratory and Rudbeck Laboratory, Uppsala, Sweden
visa färre...
 (creator_code:org_t)
2011-07-08
2011
Engelska.
Ingår i: Journal of Medical Genetics. - : BMJ Publishing Group Ltd. - 0022-2593 .- 1468-6244. ; 48:10, s. 705-709
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background Genetic factors influencing lung function may predispose to chronic obstructive pulmonary disease (COPD). The fibroblast growth factor 10 (FGF10) signalling pathway is critical for lung development and lung epithelial renewal. The hypothesis behind this study was that constitutive FGF10 insufficiency may lead to pulmonary disorder. Therefore investigation of the pulmonary functions of patients heterozygous for loss of function mutations in the FGF10 gene was performed. Methods The spirometric measures of lung function from patients and non-carrier siblings were compared and both groups were related to matched reference data for normal human lung function. Results The patients show a significant decrease in lung function parameters when compared to control values. The average FEV1/IVC quota (FEV1%) for the patients is 0.65 (80% of predicted) and reversibility test using Terbutalin resulted in a 3.7% increase in FEV1. Patients with FGF10 haploinsufficiency have lung function parameters indicating COPD. A modest response to Terbutalin confirms an irreversible obstructive lung disease. Conclusion These findings support the idea that genetic variants affecting the FGF10 signalling pathway are important determinants of lung function that may ultimately contribute to COPD. Specifically, the results show that FGF10 haploinsufficiency affects lung function measures providing a model for a dosage sensitive effect of FGF10 in the development of COPD.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)

Nyckelord

fibroblast growth factor 10
terbutaline
adult
animal experiment
animal model
article
chronic obstructive lung disease
clinical article
controlled study
forced expiratory volume
gene loss
gene mutation
genetic variability
haploinsufficiency
heterozygote
human
inspiratory capacity
lung function
mouse
nonhuman
phenotype
priority journal
sibling
signal transduction
spirometry
total lung capacity
vital capacity
Adolescent
Aged
Analysis of Variance
Animals
Female
Genetic Predisposition to Disease
Humans
Male
Mice
Mice
Transgenic
Middle Aged
Pulmonary Disease
Chronic Obstructive

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy